Enhancement of potent antibody and T-cell responses by a single-dose, novel nanoemulsion-formulated pandemic influenza vaccine

Microbes and Infection

Volumn 11, Issue 6-7, 2009, Pages 654-660

  Huang, Ming Hsi ^a   Huang, Chiung Yi ^a   Lin, Su Chen ^a   Chen, Jia Huey ^a   Ku, Chien Chun ^a   Chou, Ai Hsiang ^a   Liu, Shih Jen ^a   Chen, Hsin Wei ^a   Chong, Pele ^a   Leng, Chih Hsiang ^a  

^a NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

Author keywords

H5N1; Single dose; Vaccine delivery system

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 4; SORBITAN TRIOLEATE; SPAN; SQUALENE; UNCLASSIFIED DRUG; VIRUS ANTIBODY; VIRUS HEMAGGLUTININ;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ANTIGEN SPECIFICITY; ARTICLE; CELL PROLIFERATION; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG FORMULATION; FEMALE; HEMAGGLUTINATION INHIBITION; IMMUNIZATION; INFLUENZA; INFLUENZA VACCINATION; INFLUENZA VIRUS A H5N1; MOUSE; NANOEMULSION; NONHUMAN; PANDEMIC; PRIORITY JOURNAL; VIRUS NEUTRALIZATION;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, VIRAL; CYTOKINES; EMULSIONS; FEMALE; HEMAGGLUTINATION INHIBITION TESTS; HEXOSES; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA VACCINES; MICE; MICE, INBRED BALB C; NANOPARTICLES; NEUTRALIZATION TESTS; SQUALENE; T-LYMPHOCYTES; UBIQUITINS; VACCINES, INACTIVATED;

MUS;

EID: 67649210791     PISSN: 12864579     EISSN: 1769714X     Source Type: Journal    
DOI: 10.1016/j.micinf.2009.03.003     Document Type: Article

References (24)

1. Leroux-Roels I., Borkowski A., Vanwolleghem T., Drame M., Clement F., Hons E., Devaster J.M., and Leroux-Roels G. Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial. Lancet 370 (2007) 580-589
2. Kreijtz J.H., Suezer Y., van Amerongen G., de Mutsert G., Schnierle B.S., Wood J.M., Kuiken T., Fouchier R.A., Lower J., Osterhaus A.D., Sutter G., and Rimmelzwaan G.F. Recombinant modified vaccinia virus Ankara-based vaccine induces protective immunity in mice against infection with influenza virus H5N1. J. Infect. Dis. 195 (2007) 1598-1606
3. Hehme N., Engelmann H., Kuenzel W., Neumeier E., and Saenger R. Immunogenicity of a monovalent, aluminum-adjuvanted influenza whole virus vaccine for pandemic use. Virus Res. 103 (2004) 163-171
4. de Jong M.D., and Hien T.T. Avian influenza A (H5N1). J. Clin. Virol. 35 (2006) 2-13
5. Kistner O., Howard M.K., Spruth M., Wodal W., Bruhl P., Gerencer M., Crowe B.A., Savidis-Dacho H., Livey I., Reiter M., Mayerhofer I., Tauer C., Grillberger L., Mundt W., Falkner F.G., and Barrett P.N. Cell culture (Vero) derived whole virus (H5N1) vaccine based on wild-type virus strain induces cross-protective immune responses. Vaccine 25 (2007) 6028-6036
6. Wack A., Baudner B.C., Hilbert A.K., Manini I., Nuti S., Tavarini S., Scheffczik H., Ugozzoli M., Singh M., Kazzaz J., Montomoli E., Del Giudice G., Rappuoli R., and O'Hagan D.T. Combination adjuvants for the induction of potent, long-lasting antibody and T-cell responses to influenza vaccine in mice. Vaccine 26 (2008) 552-561
7. Singh M., Ugozzoli M., Kazzaz J., Chesko J., Soenawan E., Mannucci D., Titta F., Contorni M., Volpini G., Del Guidice G., and O'Hagan D.T. A preliminary evaluation of alternative adjuvants to alum using a range of established and new generation vaccine antigens. Vaccine 24 (2006) 1680-1686
8. O'Hagan D.T. MF59 is a safe and potent vaccine adjuvant that enhances protection against influenza virus infection. Expert Rev. Vaccines 6 (2007) 699-710
9. Ott G., Barchfeld G.L., Chernoff D., Radhakrishnan R., van Hoogevest P., and Van Nest G. MF59. Design and evaluation of a safe and potent adjuvant for human vaccines. Pharm. Biotechnol. 6 (1995) 277-296
10. Podda A. The adjuvanted influenza vaccines with novel adjuvants: experience with the MF59-adjuvanted vaccine. Vaccine 19 (2001) 2673-2680
11. E. Hanon, J. Stephenne, The use of an influenza virus an oil-in-water emulsion adjuvant to induce CD4 T-cell and/or improved B-memory cell response, WO/2006/100109, 2006.
12. M.H. Huang, A.H. Chou, S.P. Lien, H.W. Chen, C.Y. Huang, W.W. Chen, P. Chong, S.J. Liu, C.H. Leng, Formulation and immunological evaluation of novel vaccine delivery systems based on bioresorbable poly(ethylene glycol)-block-poly(lactide-co-ε-caprolactone), J. Biomed. Mater. Res. B, in press (PMID: 19280632).
13. P. Chong, D.P. Liu, A.H. Chou, J. Hsu, M.S. Lee, Y.F. Tseng, J.R. Chiang, A. Hu, S. Hsiao, A. Wu, L. Chao, S. Wu, L. Huang, M. Wong, S.C. Wu, W.C. Lian, H.Y. Chen, W.H. Chou, H.P. Tsai, H.W. Chen, C.H. Leng, S. Kuo, Emergency production of avian flu vaccines, in: Proceeding of Options for the Control of Influenza, Toronto, June 17-23, 2007 (Abstract P1405).
14. Hauge S., Madhun A.S., Cox R.J., Brokstad K.A., and Haaheim L.R. Comparison of the humoral and cellular immune responses at different immunological sites after split influenza virus vaccination of mice. Scand. J. Immunol. 64 (2006) 467-475
15. Myc A., Kukowska-Latallo J.F., Bielinska A.U., Cao P., Myc P.P., Janczak K., Sturm T.R., Grabinski M.S., Landers J.J., Young K.S., Chang J., Hamouda T., Olszewski M.A., and Baker Jr. J.R. Development of immune response that protects mice from viral pneumonitis after a single intranasal immunization with influenza A virus and nanoemulsion. Vaccine 21 (2003) 3801-3814
16. Reddy S.T., Swartz M.A., and Hubbell J.A. Targeting dendritic cells with biomaterials: developing the next generation of vaccines. Trends Immunol. 27 (2006) 573-579
17. Wang C., Ge Q., Ting D., Nguyen D., Shen H.R., Chen J., Eisen H.N., Heller J., Langer R., and Putnam D. Molecularly engineered poly(ortho ester) microspheres for enhanced delivery of DNA vaccines. Nat. Mater. 3 (2004) 190-196
18. Ansaldi F., Bacilieri S., Banfi F., Durando P., Sticchi L., Icardi G., and Gasparini R. Neutralizing and hemagglutination-inhibiting activities of antibodies elicited by the 2004-2005 influenza vaccine against drifted viruses. Clin. Vaccine Immunol. 13 (2006) 162-164
19. Ninomiya A., Imai M., Tashiro M., and Odagiri T. Inactivated influenza H5N1 whole-virus vaccine with aluminum adjuvant induces homologous and heterologous protective immunities against lethal challenge with highly pathogenic H5N1 avian influenza viruses in a mouse model. Vaccine 25 (2007) 3554-3560
20. Mosca F., Tritto E., Muzzi A., Monaci E., Bagnoli F., Iavarone C., O'Hagan D., Rappuoli R., and De Gregorio E. Molecular and cellular signatures of human vaccine adjuvants. Proc. Natl. Acad. Sci. U.S.A. 105 (2008) 10501-10506
21. B. Brancq, G. Trouve, Injectable multi-phase emulsions, United States Patent 5424067, 1995.
22. Todd C.W., Balusubramanian M., and Newman M.J. Development of adjuvant-active nonionic block copolymers. Adv. Drug Deliv. Rev. 32 (1998) 199-223
23. McElhaney J.E., Xie D., Hager W.D., Barry M.B., Wang Y., Kleppinger A., Ewen C., Kane K.P., and Bleackley R.C. T cell responses are better correlates of vaccine protection in the elderly. J. Immunol. 176 (2006) 6333-6339
24. McElhaney J.E. The unmet need in the elderly: designing new influenza vaccines for older adults. Vaccine 23 Suppl. 1 (2005) S10-S25